These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 32774817)

  • 1. Developing oncolytic
    Ebrahimi S; Makvandi M; Abbasi S; Azadmanesh K; Teimoori A
    Iran J Basic Med Sci; 2020 Jul; 23(7):937-944. PubMed ID: 32774817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Herpes Simplex Virus 1 Mutant with Point Mutations in
    Mostafa HH; Thompson TW; Konen AJ; Haenchen SD; Hilliard JG; Macdonald SJ; Morrison LA; Davido DJ
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29321311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attenuated Herpes Simplex Virus 1 (HSV-1) Expressing a Mutant Form of ICP6 Stimulates a Strong Immune Response That Protects Mice against HSV-1-Induced Corneal Disease.
    Davido DJ; Tu EM; Wang H; Korom M; Gazquez Casals A; Reddy PJ; Mostafa HH; Combs B; Haenchen SD; Morrison LA
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29950407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A knockdown of the herpes simplex virus type-1 gene in all-in-one CRISPR vectors.
    Khodadad N; Fani M; Jamehdor S; Nahidsamiei R; Makvandi M; Kaboli S; Teimoori A; Thekkiniath J
    Folia Histochem Cytobiol; 2020; 58(3):174-181. PubMed ID: 32937678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting NECTIN-1 Based on CRISPR/Cas9 System Attenuated the Herpes Simplex Virus Infection in Human Corneal Epithelial Cells In Vitro.
    Li Y; Wei Y; Li G; Huang S; Xu J; Ding Q; Hong J
    Transl Vis Sci Technol; 2022 Feb; 11(2):8. PubMed ID: 35119473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction of an IL12 and CXCL11 armed oncolytic herpes simplex virus using the CRISPR/Cas9 system for colon cancer treatment.
    Zhang N; Li J; Yu J; Wan Y; Zhang C; Zhang H; Cao Y
    Virus Res; 2023 Jan; 323():198979. PubMed ID: 36283533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR/Cas-9 vector system: targets UL-39 and inhibits Simplexvirus humanalpha1 (HSV-1) replication in vitro.
    Vasques Raposo J; Rodrigues Carvalho Barros L; Ribas Torres L; Barbosa da Silva Pinto R; De Oliveira Lopes A; Mello de Souza E; Hernan Bonamino M; Salete de Paula V
    Cell Mol Biol (Noisy-le-grand); 2023 Jul; 69(7):19-23. PubMed ID: 37715442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete and Prolonged Inhibition of Herpes Simplex Virus Type 1 Infection In Vitro by CRISPR/Cas9 and CRISPR/CasX Systems.
    Karpov DS; Demidova NA; Kulagin KA; Shuvalova AI; Kovalev MA; Simonov RA; Karpov VL; Snezhkina AV; Kudryavtseva AV; Klimova RR; Kushch AA
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The chicken chorioallantoic membrane model for isolation of CRISPR/cas9-based HSV-1 mutant expressing tumor suppressor p53.
    Kelishadi M; Shahsavarani H; Tabarraei A; Shokrgozar MA; Teimoori-Toolabi L; Azadmanesh K
    PLoS One; 2023; 18(10):e0286231. PubMed ID: 37862369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of HSV-1 infection and viral reactivation by CRISPR-Cas9 gene editing in 2D and 3D culture models.
    Bellizzi A; Çakır S; Donadoni M; Sariyer R; Liao S; Liu H; Ruan GX; Gordon J; Khalili K; Sariyer IK
    Mol Ther Nucleic Acids; 2024 Sep; 35(3):102282. PubMed ID: 39176174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation and validation of recombinant herpes simplex type 1 viruses (HSV-1) using CRISPR/Cas9 genetic disruption.
    Bommareddy PK; Peters C; Kaufman HL
    Methods Enzymol; 2020; 635():167-184. PubMed ID: 32122544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases.
    Kuroda T; Martuza RL; Todo T; Rabkin SD
    BMC Biotechnol; 2006 Sep; 6():40. PubMed ID: 16995942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CLEAR Strategy Inhibited HSV Proliferation Using Viral Vectors Delivered CRISPR-Cas9.
    Ying M; Wang H; Liu T; Han Z; Lin K; Shi Q; Zheng N; Ye T; Gong H; Xu F
    Pathogens; 2023 Jun; 12(6):. PubMed ID: 37375504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening Method for CRISPR/Cas9 Inhibition of a Human DNA Virus: Herpes Simplex Virus.
    Neuhausser WM; Oh HS; Eggan P; Angelova M; Kirchner R; Eggan KC; Knipe DM
    Bio Protoc; 2020 Sep; 10(17):e3748. PubMed ID: 33659408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective Editing of Herpes Simplex Virus 1 Enables Interferon Induction and Viral Replication That Destroy Malignant Cells.
    Liu X; He B
    J Virol; 2019 Jan; 93(2):. PubMed ID: 30404809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic Herpes Simplex Viral Therapy: A Stride toward Selective Targeting of Cancer Cells.
    Sanchala DS; Bhatt LK; Prabhavalkar KS
    Front Pharmacol; 2017; 8():270. PubMed ID: 28559846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR/Cas9-Based Genome Editing of HSV.
    Velusamy T; Gowripalan A; Tscharke DC
    Methods Mol Biol; 2020; 2060():169-183. PubMed ID: 31617178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of siRNA on HSV-1 plaque formation and relative expression levels of UL39 mRNA.
    Zhe R; Mei-Ying Z; Kitazato K; Kobayash N; Qin-Chang Z; Pei-Zhuo Z; Zhi-Rong Y; Yi-Fei W
    Arch Virol; 2008; 153(7):1401-6. PubMed ID: 18551244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody Screening System Using a Herpes Simplex Virus (HSV)-Based Probe To Identify a Novel Target for Receptor-Retargeted Oncolytic HSVs.
    Ikeda H; Uchida H; Okubo Y; Shibata T; Sasaki Y; Suzuki T; Hamada-Uematsu M; Hamasaki R; Okuda K; Yamaguchi M; Kojima M; Tanaka M; Hamada H; Tahara H
    J Virol; 2021 Apr; 95(9):. PubMed ID: 33627393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.
    Coukos G; Makrigiannakis A; Montas S; Kaiser LR; Toyozumi T; Benjamin I; Albelda SM; Rubin SC; Molnar-Kimber KL
    Cancer Gene Ther; 2000 Feb; 7(2):275-83. PubMed ID: 10770637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.